Logo image of POXEL.PA

POXEL SA (POXEL.PA) Stock Fundamental Analysis

EPA:POXEL - Euronext Paris - Matif - FR0012432516 - Common Stock - Currency: EUR

0.572  -0.01 (-1.38%)

Fundamental Rating

1

Taking everything into account, POXEL scores 1 out of 10 in our fundamental rating. POXEL was compared to 65 industry peers in the Biotechnology industry. POXEL has a bad profitability rating. Also its financial health evaluation is rather negative. POXEL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

POXEL had negative earnings in the past year.
In the past year POXEL has reported a negative cash flow from operations.
POXEL had negative earnings in each of the past 5 years.
POXEL had a negative operating cash flow in each of the past 5 years.
POXEL.PA Yearly Net Income VS EBIT VS OCF VS FCFPOXEL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -288.21%, POXEL is not doing good in the industry: 89.23% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -288.21%
ROE N/A
ROIC N/A
ROA(3y)-287.1%
ROA(5y)-189.16%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
POXEL.PA Yearly ROA, ROE, ROICPOXEL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400 -600

1.3 Margins

POXEL has a Gross Margin of 0.78%. This is comparable to the rest of the industry: POXEL outperforms 46.15% of its industry peers.
POXEL's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for POXEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-92.04%
GM growth 5YN/A
POXEL.PA Yearly Profit, Operating, Gross MarginsPOXEL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

POXEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for POXEL has been increased compared to 1 year ago.
POXEL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, POXEL has a worse debt to assets ratio.
POXEL.PA Yearly Shares OutstandingPOXEL.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
POXEL.PA Yearly Total Debt VS Total AssetsPOXEL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

POXEL has an Altman-Z score of -30.27. This is a bad value and indicates that POXEL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -30.27, POXEL is doing worse than 83.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -30.27
ROIC/WACCN/A
WACC7.57%
POXEL.PA Yearly LT Debt VS Equity VS FCFPOXEL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

POXEL has a Current Ratio of 0.26. This is a bad value and indicates that POXEL is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.26, POXEL is doing worse than 87.69% of the companies in the same industry.
A Quick Ratio of 0.26 indicates that POXEL may have some problems paying its short term obligations.
POXEL has a Quick ratio of 0.26. This is amonst the worse of the industry: POXEL underperforms 87.69% of its industry peers.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.26
POXEL.PA Yearly Current Assets VS Current LiabilitesPOXEL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.95% over the past year.
Looking at the last year, POXEL shows a very strong growth in Revenue. The Revenue has grown by 41.53%.
Measured over the past years, POXEL shows a very negative growth in Revenue. The Revenue has been decreasing by -49.84% on average per year.
EPS 1Y (TTM)70.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.59%
Revenue 1Y (TTM)41.53%
Revenue growth 3Y-33.73%
Revenue growth 5Y-49.84%
Sales Q2Q%129.64%

3.2 Future

The Earnings Per Share is expected to decrease by -32.66% on average over the next years. This is quite bad
Based on estimates for the next years, POXEL will show a very strong growth in Revenue. The Revenue will grow by 187.77% on average per year.
EPS Next Y-58.3%
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%
EPS Next 5YN/A
Revenue Next Year3450%
Revenue Next 2Y169.26%
Revenue Next 3Y187.77%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
POXEL.PA Yearly Revenue VS EstimatesPOXEL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
POXEL.PA Yearly EPS VS EstimatesPOXEL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

POXEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year POXEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
POXEL.PA Price Earnings VS Forward Price EarningsPOXEL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
POXEL.PA Per share dataPOXEL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A cheap valuation may be justified as POXEL's earnings are expected to decrease with -32.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for POXEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POXEL SA

EPA:POXEL (7/2/2025, 2:20:23 PM)

0.572

-0.01 (-1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-20 2025-05-20
Earnings (Next)07-04 2025-07-04
Inst Owners4.99%
Inst Owner ChangeN/A
Ins Owners3.3%
Ins Owner ChangeN/A
Market Cap30.75M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.04
BVpS-0.94
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -288.21%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.78%
FCFM N/A
ROA(3y)-287.1%
ROA(5y)-189.16%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-92.04%
GM growth 5YN/A
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.26
Altman-Z -30.27
F-Score4
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.59%
EPS Next Y-58.3%
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%
EPS Next 5YN/A
Revenue 1Y (TTM)41.53%
Revenue growth 3Y-33.73%
Revenue growth 5Y-49.84%
Sales Q2Q%129.64%
Revenue Next Year3450%
Revenue Next 2Y169.26%
Revenue Next 3Y187.77%
Revenue Next 5YN/A
EBIT growth 1Y43.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year204.08%
EBIT Next 3Y-1.71%
EBIT Next 5YN/A
FCF growth 1Y37.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.16%
OCF growth 3YN/A
OCF growth 5YN/A